Recent News

• 02.06.2026 - Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering
• 02.03.2026 - Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA
• 01.27.2026 - Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program
• 01.06.2026 - Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer
• 11.10.2025 - Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials
• 11.06.2025 - Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform
• 10.01.2025 - Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa
• 09.29.2025 - Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit
• 09.17.2025 - Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research

Recent Filings

• 02.05.2026 - S-1/A General form for registration of securities under the Securities Act of 1933
• 02.05.2026 - 8-A12B Registration of securities [Section 12(b)]
• 02.05.2026 - CERT Certification by an exchange approving securities for listing
• 02.04.2026 - S-1/A General form for registration of securities under the Securities Act of 1933
• 02.03.2026 - S-1 General form for registration of securities under the Securities Act of 1933
• 12.19.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 12.16.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 12.11.2025 - 8-K Current report
• 12.11.2025 - EX-99.1 EX-99.1
• 11.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]